{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:32:09Z","timestamp":1784381529929,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008793","name":"Universidad del Rosario","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the efficacy, effectiveness, and safety of Rho-kinase (ROCK) inhibitors in the management of uveitic glaucoma (UG) and ocular hypertension secondary to uveitis (OHT-SU) through a systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, EMBASE, Virtual Health Library, and medRxiv databases until October 29, 2024, for studies evaluating UG or OHT-SU patients treated with ROCK inhibitors. Eligible designs included case series with over 10 patients, cross-sectional studies, cohort studies, and randomized controlled trials. Risk of bias was assessed using the CLARITY tools and validated metrics\u00a0such as those developed by Hoy et al., Hassan Murad et al., and the RoB-2 tool. A pressure (IOP) reduction meta-analysis at different follow-up points was conducted using R software. The study was registered in PROSPERO with the CRD42024618812 number.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven studies (383 participants, 256 eyes) were analyzed. Some studies reported outcomes per eye, whereas others\u00a0reported outcomes only per patient; thus, the number of eyes reflects only explicitly reported data. Based on the risk of bias assessment, two\u00a0studies had a low risk of bias, four raised some concerns, and five were at high risk of bias. Pooled mean age was 64.2\u2009\u00b1\u200915.2\u00a0years (from 10 studies reporting age); sex distribution (50.5% male, 49.5% female, from 7 studies reporting gender).<\/jats:p>\n                    <jats:p>ROCK inhibitors achieved a statistically significant reduction in IOP at 3\u00a0months (mean difference: -9.32\u00a0mmHg, 95% CI: -17.02 to -1.62). These effects were sustained at 12\u00a0months (-7.92\u00a0mmHg, 95% CI: -10.28 to -5.56). Combination therapy enhanced pressure control.<\/jats:p>\n                    <jats:p>The most common adverse event was conjunctival hyperemia, with a pooled prevalence of 6% (95% CI: 3%-15%), followed by ocular pain and blurred vision. Importantly, no major safety differences were found between ripasudil and netarsudil. Additionally, ROCK inhibitors also improved surgical outcomes in UG patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ROCK inhibitors demonstrate significant and sustained IOP-lowering effects in UG and OHT-SU with a favorable safety profile. Their additive effect with conventional treatments and potential benefits in surgical outcomes highlight their role as promising therapeutic agents. Further clinical trials are needed to compare different ROCK inhibitors and assess their long-term safety and effectiveness in different populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-025-07111-1","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:03:50Z","timestamp":1770116630000},"page":"1527-1540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, effectiveness, and safety of rho-kinase inhibitors in uveitic glaucoma and ocular hypertension secondary to uveitis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8673-4801","authenticated-orcid":false,"given":"Blanca","family":"Aguilar-Barrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1241-0715","authenticated-orcid":false,"given":"Germ\u00e1n","family":"Mej\u00eda-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3888-3870","authenticated-orcid":false,"given":"Juanita","family":"Cardona-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Reyes-Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago David","family":"Acosta-Alzamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Santiago","family":"Escobar-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bian Andr\u00e9s","family":"Guauque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Camacho-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Suarez-Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Beltr\u00e1n-Brice\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"G\u00f3mez-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zarate-Pinz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"G\u00f3mez-Goyeneche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-1989","authenticated-orcid":false,"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"7111_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/s0021-5155(02)00549-x","volume":"46","author":"T Takahashi","year":"2002","unstructured":"Takahashi T (2002) A clinical evaluation of uveitis-associated secondary glaucoma. Jpn J Ophthalmol 46:556\u2013562. https:\/\/doi.org\/10.1016\/s0021-5155(02)00549-x","journal-title":"Jpn J Ophthalmol"},{"key":"7111_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41433-023-02757-9","volume":"38","author":"W Rojas-Carabali","year":"2024","unstructured":"Rojas-Carabali W, Mej\u00eda-Salgado G, Cifuentes-Gonz\u00e1lez C et al (2024) Prevalence and clinical characteristics of uveitic glaucoma: multicentric study in Bogot\u00e1, Colombia. Eye 38:714\u2013722. https:\/\/doi.org\/10.1038\/s41433-023-02757-9","journal-title":"Eye"},{"key":"7111_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051185","volume":"13","author":"I Halkiadakis","year":"2024","unstructured":"Halkiadakis I, Konstantopoulou K, Tzimis V et al (2024) Update on diagnosis and treatment of uveitic glaucoma. J Clin Med 13:1185. https:\/\/doi.org\/10.3390\/jcm13051185","journal-title":"J Clin Med"},{"key":"7111_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2016.06.018","volume":"787","author":"A Dibas","year":"2016","unstructured":"Dibas A, Yorio T (2016) Glucocorticoid therapy and ocular hypertension. Eur J Pharmacol 787:57\u201371. https:\/\/doi.org\/10.1016\/j.ejphar.2016.06.018","journal-title":"Eur J Pharmacol"},{"key":"7111_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4274\/tjo.galenos.2019.36589","volume":"49","author":"D Kalogeropoulos","year":"2019","unstructured":"Kalogeropoulos D, Kalogeropoulos C, Moschos MM, Sung V (2019) The management of uveitic glaucoma in children. Turk J Ophthalmol 49:283\u2013293. https:\/\/doi.org\/10.4274\/tjo.galenos.2019.36589","journal-title":"Turk J Ophthalmol"},{"key":"7111_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ajo.2022.03.026","volume":"240","author":"M Yakin","year":"2022","unstructured":"Yakin M, Kumar A, Kodati S et al (2022) Risk of elevated intraocular pressure with difluprednate in patients with non-infectious uveitis. Am J Ophthalmol 240:232\u2013238. https:\/\/doi.org\/10.1016\/j.ajo.2022.03.026","journal-title":"Am J Ophthalmol"},{"key":"7111_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/08820538.2011.588650","volume":"26","author":"MB Horsley","year":"2011","unstructured":"Horsley MB, Chen TC (2011) The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol 26:285\u2013289. https:\/\/doi.org\/10.3109\/08820538.2011.588650","journal-title":"Semin Ophthalmol"},{"key":"7111_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00417-009-1036-3","volume":"247","author":"NN Markomichelakis","year":"2009","unstructured":"Markomichelakis NN, Kostakou A, Halkiadakis I et al (2009) Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 247:775\u2013780. https:\/\/doi.org\/10.1007\/s00417-009-1036-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7111_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ogla.2024.07.010","volume":"8","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Bicket AK, Marwah S et al (2025) Incidence of acute cystoid macular edema after starting a prostaglandin analog compared with other classes of glaucoma medications. Ophthalmol Glaucoma 8:4\u201311. https:\/\/doi.org\/10.1016\/j.ogla.2024.07.010","journal-title":"Ophthalmol Glaucoma"},{"key":"7111_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00417-018-4156-9","volume":"257","author":"WD Ramdas","year":"2019","unstructured":"Ramdas WD, Pals J, Rothova A, Wolfs RCW (2019) Efficacy of glaucoma drainage devices in uveitic glaucoma and a meta-analysis of the literature. Graefes Arch Clin Exp Ophthalmol 257:143\u2013151. https:\/\/doi.org\/10.1007\/s00417-018-4156-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7111_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115576","author":"L-C Liu","year":"2024","unstructured":"Liu L-C, Chen Y-H, Lu D-W (2024) The application of rho kinase inhibitors in the management of glaucoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25115576","journal-title":"Int J Mol Sci"},{"key":"7111_CR12","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s40123-023-00820-y","volume":"12","author":"J Wang","year":"2023","unstructured":"Wang J, Wang H, Dang Y (2023) Rho-kinase inhibitors as emerging targets for glaucoma therapy. Ophthalmol Ther 12:2943\u20132957. https:\/\/doi.org\/10.1007\/s40123-023-00820-y","journal-title":"Ophthalmol Ther"},{"key":"7111_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/13543776.2019.1670812","volume":"29","author":"E Berrino","year":"2019","unstructured":"Berrino E, Supuran CT (2019) Rho-kinase inhibitors in the management of glaucoma. Expert Opin Ther Pat 29:817\u2013827. https:\/\/doi.org\/10.1080\/13543776.2019.1670812","journal-title":"Expert Opin Ther Pat"},{"key":"7111_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","volume":"256","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Katsuyama A, Matsumiya W, Nakamura M (2018) Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 256:809\u2013814. https:\/\/doi.org\/10.1007\/s00417-018-3933-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7111_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2022.2145313","volume":"32","author":"M Oydanich","year":"2024","unstructured":"Oydanich M, Roll EH, Uppuluri S, Khouri AS (2024) Clinical report of the effectiveness of netasurdil in patients with uveitic glaucoma. Ocul Immunol Inflamm 32:2\u20134. https:\/\/doi.org\/10.1080\/09273948.2022.2145313","journal-title":"Ocul Immunol Inflamm"},{"key":"7111_CR16","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1016\/j.ajo.2021.05.006","volume":"228","author":"RN Van Gelder","year":"2021","unstructured":"Van Gelder RN, Sen HN, Tufail A, Lee AY (2021) Here comes the SUN (Part 2): standardization of uveitis nomenclature for disease classification criteria. Am J Ophthalmol 228:A2\u2013A6. https:\/\/doi.org\/10.1016\/j.ajo.2021.05.006","journal-title":"Am J Ophthalmol"},{"key":"7111_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid-Based Med"},{"key":"7111_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","volume":"65","author":"D Hoy","year":"2012","unstructured":"Hoy D, Brooks P, Woolf A et al (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65:934\u2013939. https:\/\/doi.org\/10.1016\/j.jclinepi.2011.11.014","journal-title":"J Clin Epidemiol"},{"key":"7111_CR19","unstructured":"Tool to Assess Risk of Bias in Cohort Studies.\u00a0https:\/\/www.distillersr.com\/resources\/methodological-resources\/tool-to-assess-risk-of-bias-in-cohort-studies-distillersr.\u00a0Accessed 29 Oct 2024"},{"key":"7111_CR20","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"7111_CR21","unstructured":"robvis (visualization tool). In: Risk Bias Tool.\u00a0https:\/\/www.riskofbias.info\/welcome\/robvis-visualization-tool.\u00a0Accessed 29 Oct 2024"},{"key":"7111_CR22","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses. In: Cochrane.\u00a0https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10.\u00a0Accessed 29 Oct 2024"},{"key":"7111_CR23","doi-asserted-by":"publisher","DOI":"10.2174\/18743641-v16-e2206201","author":"T Mimura","year":"2022","unstructured":"Mimura T, Noma H, Inoue Y et al (2022) Early postoperative effect of ripasudil hydrochloride after trabeculectomy on secondary glaucoma: a randomized controlled trial. Open Ophthalmol J. https:\/\/doi.org\/10.2174\/18743641-v16-e2206201","journal-title":"Open Ophthalmol J"},{"key":"7111_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12325-018-0863-1","volume":"36","author":"H Tanihara","year":"2019","unstructured":"Tanihara H, Kakuda T, Sano T et al (2019) Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study. Adv Ther 36:333\u2013343. https:\/\/doi.org\/10.1007\/s12325-018-0863-1","journal-title":"Adv Ther"},{"key":"7111_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01490-1","volume":"20","author":"H Tanihara","year":"2020","unstructured":"Tanihara H, Kakuda T, Sano T et al (2020) Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study. BMC Ophthalmol 20:275. https:\/\/doi.org\/10.1186\/s12886-020-01490-1","journal-title":"BMC Ophthalmol"},{"key":"7111_CR26","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s12325-021-02023-y","volume":"39","author":"H Tanihara","year":"2022","unstructured":"Tanihara H, Kakuda T, Sano T et al (2022) Long-term intraocular pressure-lowering effects and adverse events of ripasudil in patients with glaucoma or ocular hypertension over 24 months. Adv Ther 39:1659\u20131677. https:\/\/doi.org\/10.1007\/s12325-021-02023-y","journal-title":"Adv Ther"},{"key":"7111_CR27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.18240\/ijo.2023.06.11","volume":"16","author":"R Yanai","year":"2023","unstructured":"Yanai R, Kobayashi M et al (2023) Efficacy of ripasudil in reducing intraocular pressure and medication score for ocular hypertension with inflammation and corticosteroid. Int J Ophthalmol 16:904\u2013908. https:\/\/doi.org\/10.18240\/ijo.2023.06.11","journal-title":"Int J Ophthalmol"},{"key":"7111_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcjo.2023.05.009","volume":"59","author":"M Oydanich","year":"2024","unstructured":"Oydanich M, Roll EH, Uppuluri S, Khouri AS (2024) Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma. Can J Ophthalmol 59:247\u2013252. https:\/\/doi.org\/10.1016\/j.jcjo.2023.05.009","journal-title":"Can J Ophthalmol"},{"key":"7111_CR29","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/bjophthalmol-2021-318809","volume":"106","author":"T Ma","year":"2022","unstructured":"Ma T, Sims JL, Bennett S et al (2022) High rate of conversion from ocular hypertension to glaucoma in subjects with uveitis. Br J Ophthalmol 106:1520\u20131523. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-318809","journal-title":"Br J Ophthalmol"},{"key":"7111_CR30","doi-asserted-by":"publisher","DOI":"10.7860\/jcdr\/2021\/48878.14851","author":"H NagpaL","year":"2021","unstructured":"NagpaL H, Kaur M (2021) Topical ripasudil as first line treatment for ocular hypertension in uveitis cases: ananalytic study. J Clin Diagn Res. https:\/\/doi.org\/10.7860\/jcdr\/2021\/48878.14851","journal-title":"J Clin Diagn Res"},{"key":"7111_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jcto3010002","volume":"3","author":"X Li","year":"2025","unstructured":"Li X, Balas M, Mathew DJ (2025) A Review of Ocular and Systemic Side Effects in Glaucoma Pharmacotherapy. J Clin Transl Ophthalmol 3:2. https:\/\/doi.org\/10.3390\/jcto3010002","journal-title":"J Clin Transl Ophthalmol"},{"key":"7111_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/108076803762718088","volume":"19","author":"RM Feldman","year":"2003","unstructured":"Feldman RM (2003) Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 19:23\u201335. https:\/\/doi.org\/10.1089\/108076803762718088","journal-title":"J Ocul Pharmacol Ther"},{"key":"7111_CR33","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archopht.123.11.1541","volume":"123","author":"R Kapur","year":"2005","unstructured":"Kapur R (2005) Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol 123:1541. https:\/\/doi.org\/10.1001\/archopht.123.11.1541","journal-title":"Arch Ophthalmol"},{"key":"7111_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/ceo.12163","volume":"42","author":"M Kucukevcilioglu","year":"2014","unstructured":"Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI (2014) Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Experiment Ophthalmol 42:126\u2013131. https:\/\/doi.org\/10.1111\/ceo.12163","journal-title":"Clin Experiment Ophthalmol"},{"key":"7111_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10384-012-0159-y","volume":"56","author":"SJ Kwon","year":"2012","unstructured":"Kwon SJ, Park DH, Shin JP (2012) Bilateral transient myopia, angle-closure glaucoma, and choroidal detachment induced by methazolamide. Jpn J Ophthalmol 56:515\u2013517. https:\/\/doi.org\/10.1007\/s10384-012-0159-y","journal-title":"Jpn J Ophthalmol"},{"key":"7111_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/eye.1995.22","volume":"9","author":"I Wideng\u00e5rd","year":"1995","unstructured":"Wideng\u00e5rd I, Mandahl A, T\u00f6rnquist P, Wistrand PJ (1995) Colour vision and side-effects during treatment with methazolamide. Eye 9:130\u2013135. https:\/\/doi.org\/10.1038\/eye.1995.22","journal-title":"Eye"},{"issue":"1","key":"7111_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66928-4","volume":"10","author":"A Futakuchi","year":"2020","unstructured":"Futakuchi A, Morimoto T, Ikeda Y et al (2020) Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study. Sci Rep 10(1):10308. https:\/\/doi.org\/10.1038\/s41598-020-66928-4","journal-title":"Sci Rep"},{"key":"7111_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03342-4","author":"JB Lin","year":"2024","unstructured":"Lin JB, Harris JM, Baldwin G et al (2024) Ocular effects of Rho kinase (ROCK) inhibition: a systematic review. Eye. https:\/\/doi.org\/10.1038\/s41433-024-03342-4","journal-title":"Eye"},{"key":"7111_CR39","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","volume":"125","author":"AP Tanna","year":"2018","unstructured":"Tanna AP, Johnson M (2018) Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmology 125:1741\u20131756. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.040","journal-title":"Ophthalmology"},{"key":"7111_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","volume":"126","author":"H Tanihara","year":"2008","unstructured":"Tanihara H (2008) Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 126:309. https:\/\/doi.org\/10.1001\/archophthalmol.2007.76","journal-title":"Arch Ophthalmol"},{"key":"7111_CR41","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s12325-021-01634-9","volume":"38","author":"M Araie","year":"2021","unstructured":"Araie M, Sugiyama K, Aso K et al (2021) Phase 2 randomized clinical study of netarsudil ophthalmic solution in Japanese patients with primary open-angle glaucoma or ocular hypertension. Adv Ther 38:1757\u20131775. https:\/\/doi.org\/10.1007\/s12325-021-01634-9","journal-title":"Adv Ther"},{"key":"7111_CR42","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.2147\/opth.s318897","volume":"15","author":"M Naik","year":"2021","unstructured":"Naik M, Kapur M, Gupta V et al (2021) Ripasudil endgame: role of Rho-kinase inhibitor as a last-ditch-stand towards maximally tolerated medical therapy to a patient of advanced glaucoma. Clin Ophthalmol 15:2683\u20132692. https:\/\/doi.org\/10.2147\/opth.s318897","journal-title":"Clin Ophthalmol"},{"key":"7111_CR43","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1177\/11206721211008783","volume":"31","author":"M Batra","year":"2021","unstructured":"Batra M, Gupta S, Nair AB et al (2021) Netarsudil: a new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. Eur J Ophthalmol 31:2237\u20132244. https:\/\/doi.org\/10.1177\/11206721211008783","journal-title":"Eur J Ophthalmol"},{"key":"7111_CR44","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","volume":"74","author":"KP Garnock-Jones","year":"2014","unstructured":"Garnock-Jones KP (2014) Ripasudil: first global approval. Drugs 74:2211\u20132215. https:\/\/doi.org\/10.1007\/s40265-014-0333-2","journal-title":"Drugs"},{"key":"7111_CR45","unstructured":"(2017) FDA Approves Rhopressa. In: Drugs.com.\u00a0https:\/\/www.drugs.com\/newdrugs\/aerie-pharmaceuticals-announces-u-s-fda-approval-rhopressa-netarsudil-ophthalmic-solution-0-02-4663.html.\u00a0Accessed 29 Oct 2024"},{"key":"7111_CR46","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/eye.1994.169","volume":"8","author":"P Stavrou","year":"1994","unstructured":"Stavrou P, Mitchell SM, Fox JD et al (1994) Detection of varicella-zoster virus DNA in ocular samples from patients with uveitis but no cutaneous eruption. Eye 8:684\u2013687. https:\/\/doi.org\/10.1038\/eye.1994.169","journal-title":"Eye"},{"key":"7111_CR47","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/bjo.2005.086546","volume":"90","author":"I De Schryver","year":"2006","unstructured":"De Schryver I, Rozenberg F, Cassoux N et al (2006) Diagnosis and treatment of cytomegalovirus iridocyclitis without retinal necrosis. Br J Ophthalmol 90:852\u2013855. https:\/\/doi.org\/10.1136\/bjo.2005.086546","journal-title":"Br J Ophthalmol"},{"key":"7111_CR48","unstructured":"(2015) Uveitis and glaucoma. In: Progress in brain research. Elsevier, pp 243\u2013269"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07111-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:48:47Z","timestamp":1779428927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07111-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7111"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07111-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not report any studies involving human participants or animals conducted by any of the authors. In this systematic review and meta-analysis, all data were obtained from previously published studies that had received approval from their respective institutional review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No new human participants were enrolled in this research; therefore, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors received no specific funding for this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"The authors declare no conflicts of interest related to this work. They certify that they have no affiliations with, or involvement in, any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}